Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.61 |
| ▸ | PPARG | P37231 | 14/20 | 0.61 |
| ▸ | PPARA | Q07869 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334835 | 0.92 | PPARG (0.53) | PPARDPPARGPPARANPC1RAB9A | |
| SCHEMBL335795 | 0.83 | PPARD (0.72) | PPARDPPARGPPARANPC1SMN1; SMN2 | |
| SCHEMBL334517 | 0.82 | PPARD (0.68) | PPARDPPARGPPARA | |
| SCHEMBL334519 | 0.82 | PPARD (0.62) | PPARDPPARGPPARANPC1RAB9A | |
| SCHEMBL10221023 | 0.82 | PPARD (0.61) | PPARDPPARGPPARASMN1; SMN2 | |
| SCHEMBL335794 | 0.81 | PPARD (0.62) | PPARDPPARGPPARANPC1RAB9A | |
| SCHEMBL10221033 | 0.80 | PPARD (0.59) | PPARDPPARGPPARANPC1RAB9A | |
| SCHEMBL10220820 | 0.80 | PPARD (0.65) | PPARDPPARGPPARANPC1RAB9A | |
| SCHEMBL335856 | 0.79 | PPARD (0.63) | PPARDPPARGPPARANPC1RAB9A | |
| SCHEMBL10220127 | 0.78 | PPARD (0.75) | PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.